Navigation auf uzh.ch
In the final preclinical phase of radiotracer development, we investigate the distribution, metabolism pharmacokinetics and pharmacodynamics (DMPK) of our novel imaging probes in vivo using mouse models of human disease. PET/MRI imaging combined with biodistribution data and metabolite analysis allow us to characterise our radiotracers. Our goals are, i) to validate the potential new radiotracers for measuring differential target expression in vivo, and ii) to apply hybrid PET/MRI imaging as a method for detecting changes in oncogenic signalling during disease progression and treatment. These studies also provide essential data required for subsequent clinical translation of our radiotracers.